IMPORTANT:

Investors should note that all investments involve risks (including the possibility of loss of the capital invested), prices of fund shares may go up as well as down and past performance is not indicative of future performance. Investors should read the Company's Prospectus (including the Product Key Facts Statement of the Sub-Fund and the full text of the risk factors stated therein) in detail before making any investment decision.

The Stock Exchange of Hong Kong Limited (the "SEHK"), Hong Kong Securities Clearing Company Limited ("HKSCC") and the Securities and Futures Commission (the "SFC") take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

SFC authorisation is not a recommendation or endorsement of the Sub-Fund nor does it guarantee the commercial merits of the Sub-Fund or its performance. It does not mean the Sub-Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

This document is important and requires your immediate attention. If you are in doubt about the contents of this document, you should seek independent professional financial advice.

CSOP ETF Series OFC

(the "**Company**")

(a Hong Kong public umbrella open-ended fund company with variable capital, limited liability and segregated liability between sub-funds and authorized under section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)

CSOP Hang Seng Biotech ETF
Stock Code: 3174

Announcement

Change of Index Methodology

CSOP Asset Management Limited 南方東英資產管理有限公司 (the "**Manager**") wishes to notify the Shareholders of CSOP Hang Seng Biotech ETF (the "**Sub-Fund**") that Hang Seng Indexes Company Limited (the "**Index Provider**") will implement index methodology changes regarding the underlying index of the Sub-Fund, Hang Seng Biotech Index (the "**Index**"), effective from 9 March 2026 (the "**Effective Date**").

Investors should exercise caution in dealing with the shares of the Sub-Fund. Unless otherwise defined, all capitalised terms shall have the same meaning as those in the Prospectus of the Sub-Fund.

Change of Index Methodology

The Manager hereby informs Shareholders of the Sub-Fund that the index methodology of the Index will be updated by adding Volatility Screening (to be outlined below) for non-constituent biotech companies with stock names ending with marker "B", effective from the Effective Date.

Volatility Screening:

The 12-month historical volatility[#] (i.e. standard deviation of the daily logarithmic return for the past 12 months to the data cut-off date) of eligible non-constituents should not be greater than three times the 12-month historical volatility of the Index.

[#] For securities with less than 1-month of listing history, historical volatility between its listing date and the last trading day of the month following the data cut-off date will be compared with the 12-month historical volatility of the Index as of the data cut-off date.

The changes will be applied in the index review for the period ending 31 December 2025, with all changes to be effective on the Effective Date. The index name and index vendor code of the Index will remain unchanged.

For details (including details of the index methodology, latest index information and other important news), please refer to the website of the Index Provider at https://www.hsi.com.hk/eng/indexes/all-indexes/hsbio (this website has not been reviewed by the SFC).

Impact to the Sub-Fund

The changes described in this Announcement will not materially prejudice the existing investors' rights or interests. There will not be any material changes or increase in the overall risk profile of the Sub-Fund following the changes. The changes will not affect the acceptability of the Index under the SFC's Code on Unit Trusts and Mutual Funds. The changes described in this Announcement are not expected to affect the operation and investment strategy of the Sub-Fund and/or manner in which the Sub-Fund is being managed. There are no costs and/or expenses that will be incurred in connection with the changes.

General

The above changes and consequential amendments will be reflected in the revised Prospectus of the Sub-Fund, which will be published on the Manager's website at www.csopasset.com (this website has not been reviewed by the SFC) and the HKEX's website at www.hkexnews.hk on or around the Effective Date.

If you have any queries or require further information in relation to any aspect of this Announcement, please contact our Customer Service Hotline at (852) 3406 5688 or at 2801-2803, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

By Order of the Board
CSOP Asset Management Limited
Chief Executive Officer
Ding Chen

4 February 2026

As of the date of this Announcement, the board of directors of the Manager comprises 7 Directors namely, Mr. Zhou Yi, Ms. Chen Li, Mr. Yang Xiaosong, Mr. Cai Zhongping, Ms. Ding Chen, Mr. Wang Qin and Mr. Zhang Huachen.